The stock of Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) decreased by -$0.12 on Friday to finish at $28.85, down -0.41 percent. The last five days have seen an average of 1,275,600 shares of common stock traded. 2 times new highs were reached in the current year, with a fall of -$11.71. The average number of shares traded over the last 20 days was 932,345, while the average volume over the last 50 days totaled 917,644.
ARWR stock dropped -16.35% since last month. On 08/08/23, the company’s shares reached a one-month low of $26.93. The stock touched a high of $48.48 on 05/05/23, after rallying from a low of $23.09 in 52 weeks. The price of ARWR stock has declined by -28.87% or -$11.71 this year, reaching a new high 2 times. Still, the stock price is down -40.49% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
ARWR stock investors should be aware that Arrowhead Pharmaceuticals Inc. (ARWR) stock had its last reported insider trading activity 42 days ago on Jul 03. On Jul 03, Chief Commercial Officer Oliver Tracie sold 8,925 shares at $35.31 each. This transaction resulted in the insider making $315,142. On Jun 30, Hamilton James C sold 3,000 shares at a price of US$35.53. After the transaction, the insider now owns 188,484 shares. Chief Financial Officer Myszkowski Kenneth Allen had earlier sold 15,000 shares on Jun 27 for $36.20 a share. The transaction was completed for $543,000.
Valuation Metrics
Beta for the stock is 0.99. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 12.12, the price-to-book (PB) ratio of 8.46.
Financial Health
For the three months ended June 29, Arrowhead Pharmaceuticals Inc.’s quick ratio was 6.70, while its current ratio was 6.70, indicating its ability to pay off its debt. Arrowhead Pharmaceuticals Inc.’s EBITDA margin for the year ended June 29 was -69.11%, whereas its operating margin stood at -70.50% for the same period. Based on annual data, it had gross profit of $421.74 million and revenue of $243.23 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. ARWR’s return on assets (ROA) during the last 12 months has been -22.10%. There was a -45.70% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was -45.60%.
Earnings Surprise
According to Arrowhead Pharmaceuticals Inc.’s quarterly financial report for the quarter that ended June 29, it had $346.37 million in cash and short-term investments. A lower net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $15.83 million, while revenues fell by -104.74% to $146.27 million. It was predicted that Arrowhead Pharmaceuticals Inc.’s quarterly earnings would be -$0.96, but it ended up being -$0.65, beating the consensus by -47.70%. EBITDA was -$100.38 million for the quarter. At the end of Arrowhead Pharmaceuticals Inc.’s most recent quarter ended June 29, its liabilities totaled 413.87 million, while its total debt was $82.73 million. Equity owned by shareholders amounts to $107.19 million.
Technical Picture
Here’s a quick look at Arrowhead Pharmaceuticals Inc.’s (ARWR) price momentum from a technical perspective. As of 11 August, the RSI 9-day stood at 27.28%, suggesting the stock is oversold, with a 62.63% historical volatility rate.
The stochastic %K and %D were 21.31% and 15.86% respectively, while the average true range (ATR) was 1.31. Based on the 14-day stochastic reading of 20.56%, the RSI (14) reading is 30.20%. On the 9-day MACD Oscillator, the stock is at -1.70, and the 14-day reading is at -3.34.
Analyst Ratings
In its analyst report released on July 21, 2023, TD Cowen began covering Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR). The stock was rated as an Outperform by the brokerage firm. Analysts have assigned Arrowhead Pharmaceuticals Inc. (ARWR) an Overweight rating. ARWR is a stock that is recommended for selling by 0 brokerage firms, while 3 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 1 rate it overweight and 9 others recommend it as a buy.
What is ARWR’s price target for the next 12 months?
The current consensus forecast for the stock is between $27.00 and $90.00, with a median target price of $60.00. In analyzing these forecasts, the average price target given by analysts for Arrowhead Pharmaceuticals Inc. (ARWR) is $59.69.
